TY - JOUR
T1 - Noninvasive evaluation of the beneficial effect of nisoldipine in patients with severe congestive heart failure
AU - Reicher-Reiss, H.
AU - Goldbourt, U.
AU - Herz, I.
AU - Battler, A.
AU - Neufeld, H. N.
AU - Vered, Z.
PY - 1990
Y1 - 1990
N2 - To evaluate the efficacy of nisoldipine in patients with chronic congestive heart failure, we compared its effects (20 mg/day) to those of isosorbide dinitrate (ISDN) (60 mg/day) in 20 patients with severe congestive heart failure of ischemic origin. All patients were in New York Heart Association functional class III or IV, had proven coronary artery disease, and left ventricular ejection fractions of 25 to 45%. Clinical assessment, M-mode and two-dimensional echocardiography, and resting and submaximal exercise radioisotopic multigated angiography (MUGA) were performed before and after 8 weeks of therapy. Symptomatic improvement was achieved in most patients. Exercise workload improved from 60.5 ± 5.5 to 82.5 ± 7.4 W on isosorbide dinitrate and from 62.3 ± 6.6 to 73.3 ± 4.1 W on nisoldipine (p = NS). Left ventricular diastolic and systolic volumes decreased on two-dimensional echocardiogram from 174.4 ± 16.7 and 122.2 ± 13.8 to 154.8 ± 13.2 and 108.2 ± 13.2 cc, respectively, on nisoldipine (p < 0.02 for both). Volumes did not change significantly on isosorbide dinitrate. No significant changes were observed on either M-mode or MUGA-derived resting and exercise left ventricular ejection fraction under both medications. Thus, nisoldipine appears to be effective and safe in patients with severe congestive heart failure of ischemic origin. Echocardiography and MUGA studies are feasible and useful noninvasive modalities to assess the effects of pharmacological interventions in patients with congestive heart failure.
AB - To evaluate the efficacy of nisoldipine in patients with chronic congestive heart failure, we compared its effects (20 mg/day) to those of isosorbide dinitrate (ISDN) (60 mg/day) in 20 patients with severe congestive heart failure of ischemic origin. All patients were in New York Heart Association functional class III or IV, had proven coronary artery disease, and left ventricular ejection fractions of 25 to 45%. Clinical assessment, M-mode and two-dimensional echocardiography, and resting and submaximal exercise radioisotopic multigated angiography (MUGA) were performed before and after 8 weeks of therapy. Symptomatic improvement was achieved in most patients. Exercise workload improved from 60.5 ± 5.5 to 82.5 ± 7.4 W on isosorbide dinitrate and from 62.3 ± 6.6 to 73.3 ± 4.1 W on nisoldipine (p = NS). Left ventricular diastolic and systolic volumes decreased on two-dimensional echocardiogram from 174.4 ± 16.7 and 122.2 ± 13.8 to 154.8 ± 13.2 and 108.2 ± 13.2 cc, respectively, on nisoldipine (p < 0.02 for both). Volumes did not change significantly on isosorbide dinitrate. No significant changes were observed on either M-mode or MUGA-derived resting and exercise left ventricular ejection fraction under both medications. Thus, nisoldipine appears to be effective and safe in patients with severe congestive heart failure of ischemic origin. Echocardiography and MUGA studies are feasible and useful noninvasive modalities to assess the effects of pharmacological interventions in patients with congestive heart failure.
UR - http://www.scopus.com/inward/record.url?scp=0025144954&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0025144954
SN - 1043-4356
VL - 9
SP - 35
EP - 39
JO - Journal of Cardiovascular Technology
JF - Journal of Cardiovascular Technology
IS - 1
ER -